VMI
VHCP Management II Portfolio holdings
AUM
$379M
This Quarter Return
-0.73%
1 Year Return
+424.39%
3 Year Return
+2,335.22%
5 Year Return
–
10 Year Return
–
AUM
$122M
AUM Growth
–
Cap. Flow
+$122M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
86.99%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
PDS Biotechnology
PDSB
|
$22.2M |
| 2 |
Regenxbio
RGNX
|
$15.9M |
| 3 |
Ascendis Pharma
ASND
|
$13.2M |
| 4 |
CytomX Therapeutics
CTMX
|
$11.6M |
| 5 |
Arcturus Therapeutics
ARCT
|
$7.1M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PDS Biotechnology
PDSB
$57.8M
| $22.2M | 18.21% | +1,933,582 | New | +$22.2M |
|
|
2
Regenxbio
RGNX
$451M
| $15.9M | 13.04% | +1,030,954 | New | +$15.9M |
|
|
3
Ascendis Pharma
ASND
$11.8B
| $13.2M | 10.85% | +721,152 | New | +$13.2M |
|
|
4
CytomX Therapeutics
CTMX
$336M
| $11.6M | 9.56% | +603,031 | New | +$11.6M |
|
|
5
Arcturus Therapeutics
ARCT
$462M
| $7.1M | 5.83% | +1,130,500 | New | +$7.1M |
|
6
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $5.95M | 4.89% | +259,259 | New | +$5.95M |
|
7
Lipocine
LPCN
$15.8M
| $5.43M | 4.46% | +420,000 | New | +$5.43M |
|
|
AKTX
8
Akari Therapeutics
AKTX
$24.8M
| $5.36M | 4.4% | +369,490 | New | +$5.36M |
|
|
ORKA
9
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $5.02M | 4.12% | +1,078,932 | New | +$5.02M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.58M | 3.76% | +141,611 | New | +$4.58M |
|
11
Adverum Biotechnologies
ADVM
$64.6M
| $2.67M | 2.19% | +280,000 | New | +$2.67M |
|
|
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.63M | 2.16% | +175,000 | New | +$2.63M |
|
|
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.99M | 1.64% | +315,980 | New | +$1.99M |
|